Arpraziquantel
Medication
- 1 min read
- 1 chapter
Related on Lably
Through Medication
Arpraziquantel is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
Society and culture
Legal status
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children. The applicant for this medicinal product is Merck Europe B.V. It is intended exclusively for markets outside the European Union.
Names
Arpraziquantel is the International nonproprietary name.
More in Health
Food and Drug AdministrationFederal agency of the United States Department of Health and Human ServicesCenters for Disease Control and PreventionUnited States government public health agencyNauseaMedical symptom or conditionSeizurePeriod of symptoms due to excessive or synchronous neuronal brain activityVomitingExpulsion of stomach contents via the mouth or noseIntravenous therapyMedication administered into a vein